← Back to Search

Diagnostic Test

DSC MRI for Brain Tumor

N/A

Recruiting

Led By Paula Alcaide-Leon, MD

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosed with a brain metastasis or primary brain tumour and will undergo MRI with contrast.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to end of study (up to 2 years)

Awards & highlights

Study Summary

This trial is testing whether a new MRI sequence can help distinguish between radiation necrosis and tumor recurrence.

Who is the study for?

This trial is for individuals who have been diagnosed with either a brain metastasis or primary brain tumor and are scheduled to undergo an MRI scan that uses contrast material. Participants must be able to give consent, and cannot join if they have severe kidney disease or allergies that make contrast injections unsafe for them.Check my eligibility

What is being tested?

The study is testing the use of a special type of MRI called Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI) using SAGE sequence. It aims to measure vessel density and size in the brain to tell apart radiation necrosis from tumor recurrence.See study design

What are the potential side effects?

Since this trial involves an advanced form of MRI scanning, side effects may include discomfort from lying still during the procedure, loud noises from the machine, and potential allergic reactions to the contrast dye used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a brain tumor and will have an MRI with contrast.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to end of study (up to 2 years)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to end of study (up to 2 years)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to end of study (up to 2 years) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Measurement of perfusion parameter: cerebral blood volume (CBV)

Measurement of perfusion parameter: vessel size index (VSI)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic (DSC MRI)Experimental Treatment1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,472 Previous Clinical Trials

484,904 Total Patients Enrolled

Paula Alcaide-Leon, MDPrincipal InvestigatorUniversity Health Network, Toronto

Media Library

Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI) (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT05358340 — N/A

Brain Tumor Research Study Groups: Diagnostic (DSC MRI)

Brain Tumor Clinical Trial 2023: Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI) Highlights & Side Effects. Trial Name: NCT05358340 — N/A

Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI) (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05358340 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the scale of enrollment for this clinical trial?

"Affirmative. The information found on clinicaltrials.gov suggests that this research is actively recruiting participants, having been first posted on September 24th 2021 and recently updated on May 2nd 2022. A total of 100 individuals are needed to be enrolled at one site for the study's completion."

Answered by AI

Are any additional individuals being recruited for this research endeavor?

"Confirmed. As seen on clinicaltrials.gov, the trial which was originally posted in September 2021 is still recruiting participants and has been updated as recently as May 2022. There are 100 openings for this study at a single research site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions

2021. "Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05358340.